Improving Depression Outcome by Patient-Centered Medical Management

Dr. Rush has served as a consultant for Akili, Brain Resource, Compass, Curbstone Consultant LLC, Emmes, Holmusk, Johnson & Johnson (Janssen), Liva-Nova, MindLinc, Sunovion, Taj Medical, and Takeda USA, speaking fees from Liva-Nova, and royalties from Guilford Press and the University of Texas Southwestern Medical Center (for use of the Inventory of Depressive Symptoms and its derivatives); he is named co-inventor on two U.S. patents (7,795,033 and 7,906,283, on methods to predict outcome and risk of side effects with antidepressant treatment). Dr. Thase has served as consultant or adviser for Acadia, Akili, Alkermes, Allergan (Forest, Naurex), AstraZeneca, Cerecor, Eli Lilly, Fabre-Kramer, Gerson Lehrman Group, Guidepoint Global, Janssen (Johnson & Johnson, Ortho-McNeil), Lundbeck, MedAvante, Merck, Moksha8, Nestlé (PamLab), Neuralstim, Neuronetics, NeuroRx, Novartis, Otsuka, Pfizer, Shire, Sunovion, and Takeda; he has received grant support from Acadia, the Agency for Healthcare Research and Quality, Alkermes, Allergan (Forest), AssureRx, Avanir, Axome, Forest Pharmaceuticals, Intracellular Pharmaceuticals, Janssen, Johnson & Johnson, NIMH, Otsuka, the Patient-Centered Outcomes Research Institute, and Takeda; he receives royalties from American Psychiatric Press, Guilford Publications, Herald House, and W.W. Norton; and his spouse is an employee of Peloton Advantage, which does business with Pfizer and AstraZeneca.